Surrozen
South San Francisco
About Surrozen
Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $445.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2025)
- Ticker: nasdaq:SRZN
- Website: surrozen.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Emergency Medicine, Health Care
Social Profiles
Canonical: https://fsome.com/organization/surrozen-86215 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.